Acacia Research Corporation — Q1 2012 Form 10-Q
Business context and period: The filing covers the three months ended March 31, 2012. Acacia’s operating subsidiaries acquire, license, and enforce patent rights; the company reported more than 212 patent portfolios. Quarterly results can vary with the timing and size of licensing agreements.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 / prior year-end |
|---|---|---|
| Revenue | $99.0 million | $61.1 million; up 62% |
| Operating income | $64.3 million | $20.7 million; up 211% |
| Net income attributable to Acacia | $49.9 million | $12.4 million |
| Diluted earnings per share | $1.09 | $0.34 |
| Operating margin | Approximately 65% | Approximately 34% |
| Net cash provided by operating activities | $49.0 million | $36.5 million |
| Cash and cash equivalents | $315.5 million | $314.7 million at December 31, 2011 |
| Short-term investments | $134.2 million | $6.6 million at December 31, 2011 |
| Working capital | $430.9 million | $294.9 million at December 31, 2011 |
Margins are approximate calculations from reported figures. Cash, cash equivalents, and investments totaled $451.6 million at quarter-end. Acacia reported no long-term debt or committed credit lines. Net cash used in investing activities was $276.9 million, principally reflecting the ADAPTIX acquisition and purchases of investments; financing activities provided $228.7 million, mainly from an equity offering.
Material changes and notable items
- Revenue rose 62%, primarily due to higher average revenue per executed agreement and more agreements. Acacia executed 40 new agreements, versus 35 in Q1 2011.
- Inventor royalties and contingent legal fees together fell 49% to $11.3 million, despite revenue growth. Management attributed this chiefly to a greater share of revenue coming from portfolios or agreements without those obligations.
- Marketing, general and administrative expense increased 38% to $13.7 million, including $5.1 million of noncash stock compensation, up from $2.9 million.
- Patent amortization increased to $5.1 million, including $3.3 million related to newly acquired portfolios, including ADAPTIX.
- In January, Acacia acquired ADAPTIX, a 4G wireless patent business, for $160 million cash, including $10 million cash acquired. The preliminary allocation included $150 million of patents and $36.2 million of goodwill, offset by a $36.2 million deferred tax liability; the allocation remained subject to finalization.
- In February, Acacia issued 6.122 million shares at $36.75 per share, receiving approximately $219.1 million net. Shares outstanding were approximately 49.7 million at March 31.
- The income-tax provision included a $10.2 million benefit from releasing most of the company’s deferred-tax valuation allowance following the acquisition. The reported effective tax rate was 23%; management estimated an annual rate of approximately 39%.
Outlook, risks, and controls
Management stated that cash, investments, anticipated operating cash flow, and other available credit sources should meet cash requirements through at least May 2013. It provided no specific revenue or earnings guidance. Proceeds from the February offering were intended for acquisitions, working capital, and general corporate purposes. Management noted that licensing revenue may fluctuate materially with agreement timing, portfolio activity, litigation outcomes, and licensee payments.
- Three licensees accounted for 54%, 20%, and 18% of Q1 2012 revenue, respectively, indicating substantial customer concentration.
- Patent enforcement involves litigation, legal-cost, adverse-decision, and potential sanctions or fee-award risks. Management said ordinary-course claims were not expected to materially affect the company, but adverse enforcement rulings could result in material liabilities.
- Acquisition accounting and patent valuations depend on estimates of future licensing cash flows, useful lives, and other assumptions; final ADAPTIX purchase-allocation adjustments could affect goodwill and amortization.
- Acacia disclosed that a prior material weakness concerning intra-period tax accounting was remediated by February 29, 2012, and management considered disclosure controls effective at quarter-end.
Investor verification priorities
- Check whether the unusually strong revenue and margins are repeatable, given quarterly variability and concentration in three licensees.
- Track ADAPTIX licensing results, final purchase-price allocation, and the resulting patent amortization and goodwill.
- Assess the sustainability of cash generation and the deployment of the $219.1 million equity proceeds, including acquisition spending.
- Reconcile the reported tax benefit and effective rate with future cash taxes, foreign withholding-tax credits, and the company’s estimated annual tax rate.
- Monitor patent litigation outcomes, legal spending, and any sanctions or contingent liabilities.